Two well-trained speech and language therapists conducted all the assessments, which always Ku0059436 took place in the morning, 1 hour after the last meal. The

cotton rolls were weighed before and after the procedure with an electronic scale, which is sensitive to 0.01 g. The roll under the tongue and the 2 upper vestibules rolls were weighted separately, to be defined as submandibular and parotid flow. The increase in weight during the 5-minute period was converted into milliliters of saliva per minute to determine salivary flow rate. At each assessment, the medical history was taken, especially regarding feeding, speech, coughing, and salivary aspects [18]. In addition, the parents were asked to register all possible side effects in a diary. Data analysis included descriptive statistics, the median salivary flow rates, and the median Drooling Quotient. The median salivary flow rates and Drooling Quotient were compared between the 3 categories by nonparametric statistics (Kruskal-Wallis and Mann-Whitney

U tests) because of nonnormal distribution of these measures. Missing data were rare but on occasion were adjusted by the overall mean of the group. Multivariable analyses of variance (MANOVA) with a repeated measures structure were used to identify differences in mean submandibular and parotid flow and Drooling Quotient across Vemurafenib ic50 time using baseline and 8 weeks’ assessment as variables. In addition, when either of the analyses had a significant

effect, a post hoc test was performed to determine the differences between the groups. Because we wanted to control for the type I error rate, the Bonferroni adjustment for multiple comparison was used. A successful therapy response was defined as 30% submandibular flow reduction and/or 50% Terminal deoxynucleotidyl transferase reduction of the Drooling Quotient. The 30% demand has been previously reported and is explained by the estimated measurement error of the swab method to evaluate the salivary flow rate [17]. A 50% reduction in the Drooling Quotient reflected a clinically relevant change [7]. The submandibular glands produce about 60-70% of baseline salivary flow. In the event the Drooling Quotient is reduced by 50% after botulinum toxin injections, the change of flow from the submandibular glands, being the only gland exposed to this intervention, must have added substantially to this reduction. All participants were categorized as responding to or not responding to submandibular botulinum toxin type A. MANOVA with a repeated measures structure was used to identify differences in the mean parotid flow between the responding and the nonresponding groups.